Recommendations for COVID-19 vaccination timing following monoclonal antibody or convalescent plasma therapy range from a precautionary 90 day deferral, to assessing on a case-by-case basis to no need for deferral
Only published evidence is a sub-study of the larger Bamlanivimab trial where prophylactic administration of Bamlanivimab prior to mRNA COVID-19 vaccination did not affect the immune response regardless of age, risk category or vaccine product used
No evidence currently exists for vaccination timing following the use of antiviral products such as Paxlovid or Remdesivir
Badea, A; Groot, G; Reeder, B; Dalidowicz, M; Mueller, M. Is there an optimal interval between the administration of COVID-19 early intervention therapeutic products and COVID-19 vaccination? 2022 May 10, Document no.: EOC220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 10 p. (CEST rapid review report).